Brief: Outlook Therapeutics Announces Completion Of Enrollment In Norse Eight Clinical Trial
04/09/2024 13:47
Sept 4 (Reuters) - Outlook Therapeutics Inc OTLK.O :
* OUTLOOK THERAPEUTICS® ANNOUNCES COMPLETION OF ENROLLMENT
IN
NORSE EIGHT CLINICAL TRIAL
* OUTLOOK THERAPEUTICS INC - ONS-5010 BLA RESUBMISSION
PLANNED FOR
Q1 CY2025
* OUTLOOK THERAPEUTICS: TOPLINE RESULTS FROM NORSE EIGHT
EXPECTED
IN Q4 CY2024
Source text for Eikon: ID:nGNX37M9jl
Further company coverage: OTLK.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce